According to the announcement, Suzhou Ribo Life Science Co., Ltd. (Stock Code: 6938) has fully exercised the Over-allotment Option in its Global Offering. On February 5, 2026, the Overall Coordinators, on behalf of the International Underwriters, exercised the option for 4,741,400 additional H Shares, representing approximately 15% of the total number of Offer Shares before any exercise of the Over-allotment Option. These additional H Shares are issued at HK$57.97 per share, the same as the original Offer Price.

Upon completion, the total share capital of Suzhou Ribo Life Science stands at 170,554,910 shares, compared to 165,813,510 shares prior to the Over-allotment Option exercise. The company is expected to receive net proceeds of approximately HK$262.47 million from this transaction. Listing of the Over-allotment Shares on the Main Board of the Hong Kong Stock Exchange is scheduled to begin on February 10, 2026.

The stabilization period ended on February 5, 2026, with no Shares purchased or sold in the market for price stabilization. The announcement states that the public float requirements under the Listing Rules remain satisfied following the completion of the Over-allotment Option and the conclusion of the stabilization period.